RNA-Based Vaccines and Therapeutics

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".

Deadline for manuscript submissions: closed (30 June 2025) | Viewed by 458

Special Issue Editors


E-Mail Website
Guest Editor
Board of Research Applications and Industrial Relations, Institut Pasteur, 25-28 Rue du Dr Roux, 75015 Paris, France
Interests: vaccine development; mRNA vaccines; nucleic acid-based therapeutics; public health

E-Mail Website
Guest Editor
Projeto HubRNA, Escritório de Projetos de Desenvolvimento Tecnológico, Vice Diretoria de Inovação, Bio-Manguinhos, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
Interests: cellular immunology; humoral immunology; vaccinology; innovation; RNA vaccines; RNA therapeutics; vaccine equity and access

E-Mail Website
Guest Editor
Laboratório de Tecnologia Imunológica, Departamento de Desenvolvimento Experimental e Pre-Clínico, Vice Diretoria de Inovação, Bio-Manguinhos, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
Interests: nanotechnology; protein structure and function; vaccinology; RNA vaccines; RNA therapeutics

Special Issue Information

Dear Colleagues,

This Special Issue aims to explore the groundbreaking innovations and recent advancements made in RNA-based vaccines and therapeutics, as well as their implications for global health equity. RNA technology has garnered significant attention in recent years, particularly with the emergence of RNA COVID-19 vaccines. This Special Issue delves into the underlying science, development processes, and clinical applications of RNA-based interventions across various disease areas. From elucidating the fundamental principles of RNA biology to discussing the challenges and opportunities in vaccine design and delivery, this collection of articles will offer insights from leading experts in the field. Furthermore, this Special Issue will explore the potential of RNA therapeutics beyond infectious diseases, including their application in cancer immunotherapy, genetic disorders, and regenerative medicine. Through comprehensive reviews, original research articles, and perspectives, this Special Issue aims to provide a comprehensive overview of the current state of the art and future directions in RNA-based vaccines and therapeutics.

We look forward to receiving your contributions.

Dr. Sotiris Missailidis
Dr. Patrícia Cristina Da Costa Neves
Dr. Ana Paula Dinis Ano Bom
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • RNA vaccines
  • RNA therapeutics
  • delivery systems
  • analytical and process development
  • global health implications

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

30 pages, 1628 KB  
Review
RNA Therapeutics: Delivery Problems and Solutions—A Review
by Natalia Pozdniakova, Evgenii Generalov, Alexei Shevelev and Olga Tarasova
Pharmaceutics 2025, 17(10), 1305; https://doi.org/10.3390/pharmaceutics17101305 - 7 Oct 2025
Abstract
RNA-based therapeutics offer transformative potential for treating devastating diseases. However, current RNA delivery technologies face significant hurdles, including inefficient tissue targeting, insufficient selectivity, and severe side effects, leading to the termination of many clinical trials. This review critically assesses the landscape of RNA-derived [...] Read more.
RNA-based therapeutics offer transformative potential for treating devastating diseases. However, current RNA delivery technologies face significant hurdles, including inefficient tissue targeting, insufficient selectivity, and severe side effects, leading to the termination of many clinical trials. This review critically assesses the landscape of RNA-derived medicines, examining world-renowned mRNA vaccines (Spikevax, BNT162b2/Comirnaty) and RNA-based therapeutics like Miravirsen (anti-miR-122). It details the composition and clinical trial results of numerous modified short RNA drugs (e.g., siRNAs, miRNA mimetics/inhibitors) targeting various conditions. Prospects for RNA-based medicines are analysed for diseases with substantial societal impact, such as cancer, autoimmune disorders, and infectious diseases, with a focus on evolving delivery methods, including lipid nanoparticles, viral vectors, and exosomes. RNA-mediated macrophage reprogramming emerges as a promising strategy, potentially enhancing both delivery and clinical efficacy. This review highlights that while approved RNA therapies primarily target rare diseases due to delivery limitations, novel approaches in RNA modification, targeted delivery systems, and enhanced understanding of molecular mechanisms are crucial for expanding their application to prevalent diseases and unlocking their full therapeutic potential. Full article
(This article belongs to the Special Issue RNA-Based Vaccines and Therapeutics)
Show Figures

Figure 1

Back to TopTop